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Purpose
Loss of heterozygosity (LOH) at chromosomes 1p and 16q is a poor prognostic factor in 
favorable histology Wilms tumor (FHWT). This study investigated the prevalence of LOH at
1p and 16q and evaluated its prognostic value in Korean children with FHWT.  
Materials and Methods
We analyzed 101 FHWT patients who were diagnosed between 1996 and 2016 in Korean
Society of Pediatric Hematology Oncology Group hospitals. Using paraffin-embedded kidney
tissue samples sent from each center, we reviewed LOH at 1p and 16q in each patient and
assessed the prognostic value of LOH status for clinical parameters affecting event-free
survival (EFS).
Results
Of the 101 patients, 12 (11.9%) experienced recurrence; the 3-year EFS was 87.6%. LOH
at 1p or 16q was detected in 19 patients (18.8%), with five having LOH at both 1q and 16q.
The frequency of LOH at 1p was higher among younger patients (p=0.049), but there was
no difference in LOH prevalence according to tumor stage. In the multivariate analysis, LOH
at 16q was a significant negative prognostic factor affecting EFS (3-year EFS, 73.7% vs.
91.1%; hazard ratio, 3.95; p=0.037), whereas LOH at 1p was not (p=0.786).  
Conclusion
LOH at 16q was a significant negative prognostic factor affecting outcome in Korean pedi-
atric FHWT patients. Due to the small sample size of this study, large-scale multicenter trials
are warranted to investigate the prognostic value of LOH at 1p and 16q in Korean children
with FHWT. 
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Introduction
Around 7% of malignant neoplasms occur in the kidney;
these include Wilms tumor (WT; also known as nephroblas-
toma), clear cell sarcoma of the kidney, malignant rhabdoid
tumor, and renal cell carcinoma [1,2]. WT is the most com-
mon primary kidney tumor in children and is treated with a
multimodal approach that consists of surgery, radiation ther-
apy, and anticancer drugs [3]. Based on tumor stage and
pathological findings of upfront nephrectomy, the National
Wilms Tumor Study Group (NWTSG) recommends treating
WT according to the risk of relapse [4]. In contrast, the Inter-
national Society of Pediatric Oncology advocates upfront
chemotherapy before nephrectomy, with the intensity of sub-
sequent therapies adjusted according to tumor response [5].
Attempts to treat WT patients according to the risk of tumor
recurrence using prognostic markers has led to improvement
in outcome over the past 40 years, such that the long-term
survival rate is now 90% [6].
Tumor suppressor genes contribute to tumorigenesis by
disabling the function of both normal alleles of a gene [7,8].
Loss of heterozygosity (LOH) at a chromosomal locus com-
prising a tumor suppressor gene results in functional defects
that can lead to pediatric WT [7,9]. It was recently reported
that LOH at chromosome 1p and/or 16q is associated with
high recurrence and mortality rates in WT patients. The 
National Wilms Tumor Study (NWTS)-5 reported that tumor-
specific LOH at 1p and 16q was associated with a higher risk
of relapse and death in favorable histology Wilms tumor
(FHWT), and treatment intensity was increased in these 
patients [6].
However, different investigators have reported variable
findings regarding the prognostic value of LOH at 1p and
16q [10-12]: some have shown that LOH at both loci predicts
survival, while others have found that only one or the other
affects prognosis [13]. These discrepancies could be due to
several causes, not only differences in the study populations,
but also differences in ethnic variation. The present study 
investigated the prognostic significance of LOH at 1p and
16q in a Korean pediatric FHWT cohort.
Materials and Methods
1. Patients and treatment
The study protocol was approved by the WT committee of
the Korean Society of Pediatric Hematology Oncology Group
(K-PHOG), which analyzed patient information and speci-
mens from the four participating hospitals, each of which
passed Institutional Review Board deliberation, filled out the
case report form (CRF), and sent five-panel slides for each
patient to the committee for retrospective review. All pati-
nts included in this study were diagnosed as FHWT between
1996 and 2016; examined by chest X-ray, abdominal sonog-
raphy, computed tomography, or magnetic resonance imag-
ing; staged according to the NWTSG staging system; and
treated according to National Wilms’ Tumor Study 4 (NWTS-
4) guidelines [6]. One institution modified the NWTS-4 treat-
ment guideline; initial fine needle biopsy and delayed
nephrectomy was done at 6 to 9 weeks if the largest diameter
of the tumor is greater than 8 cm (modified NWTS). The CRF
included data on the patient’s age, sex, histological findings,
staging at the time of diagnosis, surgery, radiation, chemo-
therapy, relapse, and survival.
Upfront nephrectomy was initially recommended for all
patients. However, chemotherapy was given prior to neph-
rectomy if the tumor was deemed unresectable by the sur-
geon or if the surgery was life-threatening, the tumor throm-
bus extended into the inferior vena cava above the level of
the hepatic veins, or the disease was bilateral by Doppler
sonography. Stage I-II patients received two drugs including
vincristine and actinomycin D for 18 weeks without radio-
therapy, and stage III-IV patients were treated with a three-
drug regimen consisting of vincristine, actinomycin, and
doxorubicin for 24 weeks in addition to receiving radiother-
apy. Stage V patients were treated with nephron-sparing sur-
gery and chemotherapy or delayed nephrectomy after pre-
operative chemotherapy and then postoperative chemother-
apy.
2. Histopathological examination and DNA extraction for
microsatellite analysis
Paraffin-embedded kidney specimens containing normal
and tumor tissues that were cut into 5-µm sections and
mounted on glass slides (five per patient) were sent from
participating institutions to that of the principal investigator.
Pathological diagnoses were reviewed at a central location
and tumor cells were microdissected under a microscope
from hematoxylin and eosin-stained sections. DNA was 
extracted from tumor and non-tumor sections for microsatel-
lite analysis according to standard procedures. Two tissue
sections from each case were transferred using a disposable
razor blade to 900 µL of xylene in a 1.5-mL microcentrifuge
tube. Equal volumes of 100% and 70% ethanol were added
and the samples were pelleted (10 minutes in a microcen-
trifuge), dried at 56°C, and incubated overnight in cell lysis
buffer (cat. No. 1045723, Qiagen, Valencia, CA) with 1.5 µL
of proteinase K (41 µg/mg). The proteinase K was inacti-
vated by heating the samples at 56°C for 30-60 minutes; 100
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µL of protein precipitation solution (cat. No. 1045701, Qia-
gen) was added to each sample, followed by centrifugation
for 5 minutes. The supernatant was removed and isopro-
panol was added to precipitate the DNA, which was washed
with 70% ethanol and transferred to a new 1.5-mL tube.
3. Detection of LOH at 1p and 16q
 
To detect LOH at 1p and 16q, 16 polymorphic microsatel-
lite markers were selected based on a previous study [6]. For-
ward primers were labeled with four different fluorescent
dyes (VIC, 6FAM, PET, or NED) (Table 1). Polymerase chain
reaction (PCR) amplification was performed on tumor and
normal tissue samples in triplicate using the Qiagen Multi-
plex PCR Plus Kit (Hilden, Germany) under the following
conditions: 95°C for 10 minutes; five cycles of 95°C for 20 sec-
onds, 60°C for 90 seconds (1°C in each cycle), and 72°C for
1 minute; 30 cycles of 95°C for 20 seconds, 55°C for 90 sec-
onds, and 72°C for 1 minute; and 60°C for 30 minutes. PCR
products were examined using a 3500xL Dx Genetic Ana-
lyzer (Thermo Fisher Scientific, Waltham, MA) and LOH was
detected using GeneMapper v.4.1 software (Thermo Fisher
Scientific) according to the manufacturer’s instructions.
4. Statistical analysis
Event-free survival (EFS) refers to the time from diagnosis
to the first occurrence of progression, relapse after response
or death from any cause. Overall survival (OS) was defined
as the time from diagnosis to the day of death or last follow
up. EFS and OS were calculated with the Kaplan-Meier
method, and the log-rank test and the Cox proportional haz-
ards model were used for uni- and multivariate analyses, res-
pectively. The chi-square test was used to compare the con-
tingency tables. Two-sided p-values < 0.05 were considered
statistically significant.
5. Ethical statement
This study was performed in accordance with the ethical
guidelines of the “World Medical Association Declaration of
Helsinki-Ethical Principles for Medical Research Involving
Human Subjects.” This study was approved by the Institu-
tional Review Board of participating institutions and Ajou
University Hospital (IRB No. AJIRB-BMR-OBS-16-143). Writ-
ten informed consent was waived from the IRB.
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Results
A total of 101 FHWT patients were enrolled in the study.
The median age was 2.8 years (range, 0.3 to 10.4 years). The
male-to-female ratio (48:53) was 1.04. The characteristics of
the study population are summarized in Table 2. Among the
patients, 43 (42.6%) and 52 (51.5%) had tumors in the right
and left kidneys, respectively, whereas six (5.9%) had tumors
in both kidneys. Eleven patients showed distant metastasis
to the lung. Upfront nephrectomy was performed in 54 pati-
ents and delayed nephrectomy in 47; the latter was perfor-
med after preoperative chemotherapy since 37 cases were
deemed inoperable by the surgeon, with six cases of bilateral
disease and four in which the tumor thrombus extended into
Table 2. Characteristics of patients with favorable histol-
ogy Wilms tumors
NWTS-4, National Wilms’ Tumor Study 4.  
Patient characteristic
No. of patients (%)
(n=101)
Age at diagnosis (yr)
Mean (range) 2.8 (0.3-10.4)
< 2 52 (51.5)
2-10 23 (22.8)
> 10 26 (25.7)
Sex
Male 48 (47.5)
Female 53 (52.5)
Primary tumor site
Right 43 (42.6)
Left 52 (51.5)
Both 6 (5.9)
Stage
I 25 (24.8)
II 15 (14.9)
III 43 (42.6)
IV 12 (11.9)
V 6 (5.9)
Treatment strategy
NWTS-4 53 (52.5)
Modified NWTS-4 48 (47.5)
Nephrectomy
Upfront 54 (53.4)
Delayed 47 (46.5)
Metastasis to lung at diagnosis 11 (10.9)
Loss of heterozygosity for 1p/16q
1p only 14 (13.9)
16q only 14 (13.9)
Both 1p and 16q 5 (5.0)
Pa
tie
nt
No
. o
f p
ati
en
ts 
(%
)
ch
ar
ac
ter
ist
ic
1p
 (
)
1p
 (+
)
p-
va
lu
e
16
q (
)
16
q (
+)
p-
va
lu
e
1p
 on
ly
16
q o
nl
y
1p
 an
d 1
6q
No
ne
p-
va
lu
e
(n
=8
2)
(n
=1
9)
(n
=8
2)
(n
=1
9)
(n
=1
4)
(n
=1
4)
(n
=5
)
(n
=6
8)
Ag
e a
t d
iag
no
sis
 (y
r)
< 2
 
43
 (5
2.4
)
9 (
47
.4)
0.0
49
42
 (5
1.2
)
10
 (5
2.6
)
0.4
27
8 (
57
.1)
9 (
64
.3)
1 (
20
.0)
34
 (5
0.0
)
0.1
16
2-4
 
15
 (1
8.3
)
8 (
42
.1)
17
 (2
0.7
)
6 (
31
.6)
5 (
35
.7)
3 (
21
.4)
3 (
60
.0)
12
 (1
7.6
)
> 4
 
24
 (2
9.3
)
2 (
10
.5)
23
 (2
8.0
)
3 (
15
.8)
1 (
7.1
)
2 (
14
.3)
1 (
20
.0)
22
 (3
2.4
)
St
ag
e
I
19
 (2
3.2
)
6 (
31
.6)
0.4
11
24
 (2
9.3
)
1 (
5.3
)
0.0
86
6 (
42
.9)
1 (
7.1
)
0 (
18
 (2
6.5
)
0.2
26
II
13
 (1
5.9
)
2 (
10
.5)
12
 (1
4.6
)
3 (
15
.8)
2 (
14
.3)
3 (
21
.4)
0 (
10
 (1
4.7
)
III
36
 (4
3.9
)
7 (
36
.8)
30
 (3
6.6
)
13
 (6
8.4
)
3 (
21
.4)
9 (
64
.3)
4 (
80
.0)
27
 (3
9.7
)
IV
8 (
9.8
)
4 (
21
.1)
11
 (1
3.4
)
1 (
5.3
)
3 (
21
.4)
0 (
1 (
20
.0)
8 (
11
.8)
V
6 (
7.3
)
0 (
5 (
6.1
)
1 (
5.3
)
0 (
1 (
7.1
)
0 (
5 (
7.4
)
Ta
bl
e 3
.P
re
va
len
ce
 of
 lo
ss 
of
 he
ter
oz
yg
os
ity
 fo
r 1
p a
nd
 16
q a
cc
or
di
ng
 to
 ag
e a
nd
 di
se
as
e s
tag
e
VOLUME 52 NUMBER 2 APRIL 2020  441
Jun Eun Park, LOH at 16q Is a Negative Prognostic Factor in FHWT
the inferior vena cava above the level of the hepatic veins.
Forty patients received radiotherapy.
The status of LOH at 1p and 16q in the patients is shown
in Table 3. There were 19 patients (18.8%) with LOH at 1p
and 16q respectively, including five exhibiting LOH at both
loci. The frequency of LOH at 1p was higher among younger
patients (p=0.049), especially those under 4 years of age.
There was no difference in LOH prevalence according to
tumor stage (Table 3).
Among the 101 patients, there were 12 recurrences and two
deaths. The 3-year OS and EFS of all patients were 98.0% and
87.6%, respectively. The 3-year EFS rate was 89.5% in pati-
ents with and 87.2% in those without LOH at 1p (p=0.798
[log-rank test]) (Fig. 1A). The 3-year EFS rate was lower in
patients with LOH than in those without LOH at 16q (73.7%
vs. 91.1%, p=0.047 [log-rank test]) (Fig. 1B). Patients with
LOH at both 1p and 16q did not show a lower EFS rate than
those in the other groups (Fig. 1C).
A multivariate analysis showed that LOH at 16q was a sig-
nificant negative prognostic factor for EFS (hazard ratio, 3.95;
p=0.037), which was not true of LOH at 1p (hazard ratio,
0.83; p=0.817) (Table 4).
Discussion
There has been significant progress in the treatment of
FHWT over the past 30 years, and the survival rate is now
about 90% [14]. This excellent outcome is the result of a mul-
timodal approach that combines surgery, chemotherapy, and
radiation therapy according to tumor stage and histology.
Additionally, tumors at high risk of recurrence are treated
more aggressively than those at low risk, such that overtreat-
ment can be avoided in the latter cases [15]. Recently, efforts
have been made to identify new molecular markers that can
be used to predict tumor recurrence by stratifying high- and
low-risk patients, which can ultimately prolong survival by
reducing long-term treatment sequelae [7,9]. There have been
many reports of LOH in relation to the risk of recurrence of
WT, for instance at 1p, 11q, 16q, and 22q [10,13,16]. Of these,
LOH at 1p and LOH 16q are the most widely investigated
and were the focus of the present work.
In our study, 19 patients each out of 101 (18.9%) had LOH
at 1p and 16q. We compared these rates to the ones reported
in other studies (Table 5). Of the 232 WT patients enrolled in
NWTS-3 and -4, 21 patients (12%) had LOH at 1p and 35
(17%) at 16q [10]. In NWTS-5, 196 out of 1,727 FHWT patients
(11.3%) had LOH at 1p and 301 (17.4%) had LOH at 16q [4].
Of the 426 FHWT patients enrolled in the UKW 1-3 trials, the
prevalence of LOH at 1p and 16q was 10.3% and 17.4%, res-
pectively [11]; among the 125 patients who participated in
the AIEOP-TW-2003 trial, the rates were 19% and 15%, res-
pectively [13]; and in an Egyptian FHWT cohort (n=100), the
rates were 16% and 25%, respectively [12]. Thus, with the 
exception of one report [12], the prevalence of LOH at 1p and
16q is about 10%-19% and 14%-20%, respectively, whereas
the proportion of patients with both alterations is between
Fig. 1.  Event-free survival rates according to loss of het-
erozygosity (LOH) at 1p (A) and 16q (B) and four groups
classified as 1p only, 16q only, none, and both (C).
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2.6% and 5% (i.e., 4.6% [4], 2.6% [11], and 4% [13]). Five out
of 101 patients in our study had LOH at both 1p and 16q,
which is comparable to the rates in these other studies.
The frequencies of LOH at 1p and 16q are higher among
FHWT patients over 4 years old [4], and lower in patients
younger than 2 years old [12]. One study found that the fre-
quency LOH at 1p but not at 16q increased after 4 years of
age [11]. Others have shown a low prevalence of LOH at 1p
but not at 16q in patients under 2 years old [13]. In our study,
the rate of LOH at 1p was higher among younger FHWT 
patients (p=0.045), especially in those under 4 years old
(Table 3). These same age-group differences in the frequency
of LOHs appearing among the reports may represent inter-
racial biological differences in WTs. It was reported that the
Table 4.  Event-free survival rates and hazard ratio according to age, stage, and LOH at 1p and 16q status (multivariate
analysis)
LOH, loss of heterozygosity; CI, confidence interval; NWTS-4, National Wilms’ Tumor Study 4. 
Event-free survival Hazard ratio p-value(3-year) (%) (95% CI)
Age (yr)
< 2 90.0 1 (
2-4 91.3 0.84 (0.15-4.53) 0.835
> 4 79.6 2.40 (0.67-8.55) 0.176
Stage
I-II 90.6 1 (
III-V 84.5 1.11 (0.24-5.15) 0.893
Treatment strategy
NWTS-4 88.2 1 (
Modified NWTS-4 86.9 0.73 (0.15-3.51) 0.695
LOH 1p
Absent 82.7 1 (
Present 89.5 0.83 (0.17-4.01) 0.817
LOH 16q
Absent 91.1 1 (
Present 73.7 3.95 (1.08-14.39) 0.037
Table 5.  Summary of previous studies on the prevalence and hazard ratio of relapse risk associated with LOH at 1p or/and
16q
LOH, loss of heterozygosity; HR, hazard ratio; RR, relative risk (Cox model for relapse or events for specific LOH); NWTS-
4, National Wilms’ Tumor Study 4; CI, confidence interval. a)Event-free survival rate according to the Kaplan-Meier analysis
and compared with the log-rank test.
Study Source of No. of Prevalence of LOH  HR or RR p-valuestudy patients 1p/16q/both (%)
Grundy et al. [10] NWTS-3,4 232 12/17/4 RR 3.3 for 16q vs. none 0.01
Grundy et al. [6] NWTS-5 1,727 11.3/17.4/4.6 Stage I-II, RR 2.9 (95% CI, 1.51-5.49) for 0.001
both vs. none, 1p only, and 16q only
stage III-IV, RR 2.4 (95% CI, 1.20-4.82) for 
both vs. none, 1p only, and 16q only
Messahel et al. [11] UKW 1-3 426 10.3/17.4/2.6 HR 2.64 (95% CI, 1.47-4.92) for 16q vs. none < 0.001
Spreafico et al. [13] AIEOP-TW-2003 125 19/14/4 HR 4.1 (95% CI, 1.60-10.8) for 1p vs. none 0.0009
Fawzy et al. [12] National Cancer 100 26/25/12 53.8%a), 50% for 16q only, 0.007
Institute, Egypt and both vs. 1p only
This study K-PHOG 101 18.8/18.8/5 HR 3.84 (95% CI, 1.31-13.0) for 16q vs. none 0.031
VOLUME 52 NUMBER 2 APRIL 2020  443
Jun Eun Park, LOH at 16q Is a Negative Prognostic Factor in FHWT
frequency of LOH at 1p or 16q increases with tumor stage
[12]; however, in most other studies [6,11,13] including ours,
there was no association between the frequency of these alte-
rations and tumor stage.
Several studies have investigated whether LOH at 1p and/
or 16q can predict FHWT recurrence and patient survival
(Table 5). NWTS-5 is the largest of these studies to date; it
was prospective in nature and used stage-specific treatment,
and showed that LOH at both 1p and 16q loci was associated
with worse prognosis [4]. In NWTS-3 and -4, which preceded
NWTS-5, LOH at 16q was associated with 3.3- and 12-fold
higher rates of relapse and mortality, but LOH at 1p tended
to increase recurrence and mortality rates without statisti-
cally significant [2,10]. In this study, it is thought that the pre-
ceding NWTS-3,4 study was a statistical difference caused
by the smaller sample sizes than the NWTS-5 study.
However, it is thought that there would be another reason
for different results in determining LOH(s) at 1q and/or 16q
as prognostic factor(s). In a study of 125 children with FHWT
treated with the AIEOP-TW-2003 protocol which was con-
ducted in Italy from 2003 to 2008, LOH at 1p was associated
with worse disease-free survival [13]. Meanwhile, in the
UKW 1-3 trials conducted in the United Kingdom with a rel-
atively large number of subjects, 426 FHWT patients, LOH
at 16q but not at 1p was also associated with a higher risk of
relapse and death [11]. In a study of Egyptian FHWT pati-
ents, LOH at 16q alone or in combination with LOH at 1p
had a higher recurrence rate and lower 3-year EFS [12]. It can
be inferred that genetic variability of the WT may have racial
differences to produce different outcomes for each country
that conducted the study. In our study, EFS was lower in 
patients with LOH at 1p only or at both 1p and 16q compared
with those with neither alteration; this was not statistically
significant, possibly due to our small sample size. Nonethe-
less, our results show that only LOH 16q negatively affects
prognosis, which is consistent with previous findings [4,10-
12]. This result is thought to reflect racial differences, as
stated earlier in the study conducted in United Kingdom,
Egypt, and Italy.
Only cases of LOH at both 1p and 16q in FHWT stages 
I-IV are stratified into poor prognosis groups and receive 
additional intensive chemotherapy, although both types of
alteration show a low prevalence of 4% [6]. Thus, the abso-
lute number of patients who would benefit from clinical deci-
sions made based on the identification of LOH may be rela-
tively small if they were classified as high risk and given 
intensive chemotherapy [13]. In our study, five patients
among the 19 with LOH at 16q experienced recurrence; 
assuming that this group be received more aggressive treat-
ment in the future study, the remaining 14 will be likely
overtreated. Therefore, it is important that patients are strat-
ified with higher statistical power and treated in combination
with other risk factors rather than classified as a recurrent
risk group based solely on detection of LOH at 16q [9].
The limitation of our study is that although it was a nation-
wide study conducted by K-PHOG the sample size was rel-
atively small, this is especially true for LOH at 1p that is
statistically insignificant. Second, the study was retrospective
and therefore did not have a uniform staging system and
treatment strategy. Therefore, the next study needs a pro-
spective study with a uniformed staging system and treat-
ment strategy.
This study is meaningful in that it is the first to identify
LOH at 16q as a significant negative prognostic factor affect-
ing outcome in Korean pediatric FHWT patients. However,
this study is limited to its small sample size, large-scale mul-
ticenter trials are warranted to investigate the prognostic
value of LOH at 1p and 16q in Korean children with FHWT.
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